Is GANX or MRKR more profitable?

Marker Therapeutics' return on equity of -56.96% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Marker Therapeutics N/A -56.96% -47.82%

Which has higher earnings and valuation, OKYO or MRKR?

OKYO Pharma has higher earnings, but lower revenue than Marker Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Marker Therapeutics $3.55M 4.93 -$12.16M -$0.41 N/A

Is OKYO or MRKR more profitable?

OKYO Pharma's return on equity of 0.00% beat Marker Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Marker Therapeutics N/A -56.96% -47.82%

Do analysts recommend MRKR or APLM?

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 852.38%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Marker Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, MRKR or APLM?

Apollomics has higher revenue and earnings than Marker Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marker Therapeutics $3.55M 4.93 -$12.16M -$0.41 N/A Apollomics $8.50M 8.10 -$10.94M N/A N/A

Is MRKR or APLM more profitable?

Apollomics' return on equity of 0.00% beat Marker Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Marker Therapeutics N/A -56.96% -47.82% Apollomics N/A N/A N/A

Is RNTX or MRKR more profitable?

Rein Therapeutics' return on equity of 0.00% beat Marker Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -63.69% Marker Therapeutics N/A -56.96% -47.82%

Marker Therapeutics (MRKR) Competitors

$1.05 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.08 +0.03 (+2.95%)

As of 10/2/2026 07:30 PM Eastern

Compare

MRKR vs. GANX, GOSS, OKYO, APLM, and RNTX

Should you buy Marker Therapeutics stock or one of its competitors? Marker Therapeutics's main competitors and comparable companies include Gain Therapeutics (GANX), Gossamer Bio (GOSS), OKYO Pharma (OKYO), Apollomics (APLM), and Rein Therapeutics (RNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Marker Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Gain Therapeutics had 4 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Gain Therapeutics and 0 mentions for Marker Therapeutics. Gain Therapeutics' average media sentiment score of 0.43 beat Marker Therapeutics' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gain Therapeutics	Neutral
Marker Therapeutics	Neutral

Marker Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,492.49	-$20.16M	-$0.50	N/A
Marker Therapeutics	$3.55M	4.93	-$12.16M	-$0.41	N/A

Marker Therapeutics' return on equity of -56.96% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Marker Therapeutics	N/A	-56.96%	-47.82%

Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gain Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 338.60%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 852.38%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Marker Therapeutics beats Gain Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Gossamer Bio?

Marker Therapeutics (NASDAQ:MRKR) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Marker Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	N/A	-56.96%	-47.82%
Gossamer Bio	-235.00%	N/A	-112.04%

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 852.38%. Gossamer Bio has a consensus target price of $256.00, suggesting a potential upside of 2,290.29%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Marker Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Marker Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	4.93	-$12.16M	-$0.41	N/A
Gossamer Bio	$48.47M	1.35	-$170.37M	-$56.00	N/A

Marker Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

In the previous week, Gossamer Bio had 4 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Gossamer Bio and 0 mentions for Marker Therapeutics. Gossamer Bio's average media sentiment score of 0.68 beat Marker Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Gossamer Bio	Positive

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 4.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Gossamer Bio beats Marker Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, OKYO Pharma had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for OKYO Pharma and 0 mentions for Marker Therapeutics. OKYO Pharma's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
OKYO Pharma	Neutral
Marker Therapeutics	Neutral

OKYO Pharma currently has a consensus price target of $5.67, suggesting a potential upside of 285.49%. Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 852.38%. Given Marker Therapeutics' higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

OKYO Pharma has higher earnings, but lower revenue than Marker Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Marker Therapeutics	$3.55M	4.93	-$12.16M	-$0.41	N/A

OKYO Pharma has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

OKYO Pharma's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Marker Therapeutics	N/A	-56.96%	-47.82%

Summary

OKYO Pharma beats Marker Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Marker Therapeutics compare to Apollomics?

Marker Therapeutics (NASDAQ:MRKR) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 852.38%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Marker Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Marker Therapeutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Apollomics	Neutral

Marker Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Apollomics has higher revenue and earnings than Marker Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	4.93	-$12.16M	-$0.41	N/A
Apollomics	$8.50M	8.10	-$10.94M	N/A	N/A

Apollomics' return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	N/A	-56.96%	-47.82%
Apollomics	N/A	N/A	N/A

Summary

Apollomics beats Marker Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Marker Therapeutics compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Rein Therapeutics' return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
Marker Therapeutics	N/A	-56.96%	-47.82%

Marker Therapeutics has higher revenue and earnings than Rein Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
Marker Therapeutics	$3.55M	4.93	-$12.16M	-$0.41	N/A

In the previous week, Rein Therapeutics had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Rein Therapeutics and 0 mentions for Marker Therapeutics. Rein Therapeutics' average media sentiment score of 1.20 beat Marker Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rein Therapeutics	Positive
Marker Therapeutics	Neutral

Rein Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 649.34%. Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 852.38%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rein Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

Summary

Marker Therapeutics beats Rein Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.51M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-2.56	13.00	274.71	26.04
Price / Sales	4.93	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.04	16.57	10.93	6.31
Net Income	-$12.16M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-8.70%	-2.97%	-2.00%	-1.66%
1 Month Performance	-11.02%	-10.82%	-6.19%	-4.68%
1 Year Performance	9.96%	19.00%	8.03%	1.57%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	1.6752 of 5 stars	$1.05 flat	$10.00 +852.4%	+10.0%	$17.51M	$3.55M	N/A	60	Short Interest Increase
GANX Gain Therapeutics	1.982 of 5 stars	$1.66 -6.5%	$7.50 +353.2%	-10.9%	$72.22M	$50K	N/A	21	News Coverage Positive News
GOSS Gossamer Bio	2.9519 of 5 stars	$11.53 +0.0%	$256.00 +2,121.3%	-94.8%	$70.65M	$53.29M	N/A	162	Gap Up
OKYO OKYO Pharma	2.1821 of 5 stars	$1.33 -3.2%	$5.67 +327.4%	-28.3%	$69.59M	N/A	N/A	5	News Coverage
APLM Apollomics	1.6174 of 5 stars	$23.95 +0.5%	N/A	+28.4%	$69.18M	$8.50M	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. GANX, GOSS, OKYO, APLM, and RNTX

How does Marker Therapeutics compare to Gain Therapeutics?

Summary

How does Marker Therapeutics compare to Gossamer Bio?

Summary

How does Marker Therapeutics compare to OKYO Pharma?

Summary

How does Marker Therapeutics compare to Apollomics?

Summary

How does Marker Therapeutics compare to Rein Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. GANX, GOSS, OKYO, APLM, and RNTX

How does Marker Therapeutics compare to Gain Therapeutics?

Does the media favor GANX or MRKR?

Which has stronger valuation and earnings, GANX or MRKR?

Is GANX or MRKR more profitable?

Which has more risk & volatility, GANX or MRKR?

Do institutionals and insiders believe in GANX or MRKR?

Do analysts rate GANX or MRKR?

Summary

How does Marker Therapeutics compare to Gossamer Bio?

Is MRKR or GOSS more profitable?

Do analysts recommend MRKR or GOSS?

Which has higher earnings and valuation, MRKR or GOSS?

Which has more risk and volatility, MRKR or GOSS?

Does the media favor MRKR or GOSS?

Do insiders & institutionals have more ownership in MRKR or GOSS?

Summary

How does Marker Therapeutics compare to OKYO Pharma?

Do institutionals and insiders believe in OKYO or MRKR?

Does the media prefer OKYO or MRKR?

Do analysts prefer OKYO or MRKR?

Which has higher earnings and valuation, OKYO or MRKR?

Which has more volatility & risk, OKYO or MRKR?

Is OKYO or MRKR more profitable?

Summary

How does Marker Therapeutics compare to Apollomics?

Do institutionals & insiders hold more shares of MRKR or APLM?

Do analysts recommend MRKR or APLM?

Does the media favor MRKR or APLM?

Which has more volatility & risk, MRKR or APLM?

Which has stronger valuation & earnings, MRKR or APLM?

Is MRKR or APLM more profitable?

Summary

How does Marker Therapeutics compare to Rein Therapeutics?

Is RNTX or MRKR more profitable?

Which has preferable earnings and valuation, RNTX or MRKR?

Does the media prefer RNTX or MRKR?

Do analysts recommend RNTX or MRKR?

Do insiders & institutionals hold more shares of RNTX or MRKR?

Which has more risk and volatility, RNTX or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools